Currently, treatment for multiple system atrophy (MSA) is symptomatic; there are no available therapies designed to slow disease progression. This represents a huge unmet need for this patient community.…
The month of March has been declared to be Multiple System Atrophy Awareness Month, thanks to a campaign headed by the MSA Coalition. Multiple System Atrophy (MSA) Multiple system atrophy…
Nancy Green and Judi Beckerleg first met nearly 22 years ago in 1999. After Judi moved to Arizona, she began working as an aide in Nancy's classroom, where Nancy taught…
CurePSP has just announced their latest Venture Grant recipients. These grants total $320,000 and will all support the research of neurodegenerative disease treatments. CurePSP gives these grants twice every year.…
A study found on Medscape confirms that the human immune system and the human brain are the most complicated in our biological systems. The two systems are responsible for…
A local radio host and police dispatcher known as Dr. Rock to his audience in Bakersfield, California has recently passed away due to multiple system atrophy (MSA). You may recognize…
In mid-July 2021, biotechnology company Alterity Therapeutics ("Alterity") shared the publication of new data regarding ATH434 for patients with multiple system atrophy (MSA). The data comes from a preclinical…
We seldom see articles about multiple system atrophy (MSA also called Shy-Drager syndrome). The disease is extremely rare and currently, there is no effective treatment. But according to a recent…
Recently, the Michael J. Fox Foundation (MJFF) awarded $1.4 million in funding for Modag, a drug developer whose solutions treat patients with neurodegenerative diseases. In fact, says Parkinson's News…
At the virtual Alzheimer's Association International Conference (AAIC), AC Immune reported positive preclinical trial data for ACI-12589, their forward-thinking diagnostic tool. ACI-12589 is a non-invasive alpha-synuclein positron emission tomography…
According to a story from Medical Xpress, a new technological approach developed at the University of Texas Health Science Center at Houston will allow doctors to distinguish between Parkinson's disease…
According to a story from PR Newswire, the biopharmaceutical company Biohaven Pharmaceutical Holding Company, Ltd. has announced that the first patient has signed up for the company's phase 3 clinical…
According to a story from Southwest Journal, retired professor Karen Warren was first diagnosed in 2015 with multiple system atrophy, a lethal neurodegenerative disorder. The disease carries an unpleasant group…
According to a story from McGill University, a group of Canadian researchers have discovered a mutation in the French-Canadian population that is linked to diseases including multiple system atrophy, Parkinson's…
According to Newswise, new findings indicate that electrical stimulation of the spinal cord and brain may be effective in treating symptoms of a group of rare neurological movement disorders, neurodegenerative ataxias.…
Prana Biotechnology has announced that it has begun recruiting healthy volunteers for its Phase I clinical trial of the experimental drug PBT434. The drug is thought to affect processes linked…
According to a story from businesswire.com, the company Prana Biotechnology Ltd recently announced that it is beginning the recruitment process for its Phase 1 clinical trial of its investigational product…
Neurologists working at the NYU School of Medicine have developed a test that can identify some rare degenerative brain diseases, reports NYU Langone Health. Published in the Annals of Neurology…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
